Lenvatinib May Drastically Change the Treatment Landscape of Hepatocellular Carcinoma.
作者信息
Kudo Masatoshi
机构信息
Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka-Sayama, Japan.
出版信息
Liver Cancer. 2018 Mar;7(1):1-19. doi: 10.1159/000487148. Epub 2018 Feb 15.
Abstract
摘要
相似文献
1
Lenvatinib May Drastically Change the Treatment Landscape of Hepatocellular Carcinoma.仑伐替尼可能会极大地改变肝细胞癌的治疗格局。
Liver Cancer. 2018 Mar;7(1):1-19. doi: 10.1159/000487148. Epub 2018 Feb 15.
2
Partial Splenic Embolization for Lenvatinib Therapy-associated Thrombocytopenia Among Patients With Hepatocellular Carcinoma.部分脾栓塞治疗肝癌患者仑伐替尼治疗相关血小板减少症。
Anticancer Res. 2019 Dec;39(12):6895-6901. doi: 10.21873/anticanres.13909.
3
Carnitine insufficiency is associated with fatigue during lenvatinib treatment in patients with hepatocellular carcinoma.卡尼汀不足与肝癌患者接受仑伐替尼治疗期间的疲劳有关。
PLoS One. 2020 Mar 3;15(3):e0229772. doi: 10.1371/journal.pone.0229772. eCollection 2020.
4
Change in arterial tumor perfusion is an early biomarker of lenvatinib efficacy in patients with unresectable hepatocellular carcinoma.动脉肿瘤灌注的变化是不可切除肝细胞癌患者仑伐替尼疗效的早期生物标志物。
World J Gastroenterol. 2019 May 21;25(19):2365-2372. doi: 10.3748/wjg.v25.i19.2365.
5
Percutaneous transvenous shunt occlusion for portosystemic encephalopathy due to lenvatinib administration to a patient with hepatocellular carcinoma and portosystemic shunt.经皮经静脉分流闭塞术治疗因肝癌伴门体分流患者服用乐伐替尼所致的门体性脑病
Clin J Gastroenterol. 2019 Aug;12(4):341-346. doi: 10.1007/s12328-019-00938-2. Epub 2019 Jan 31.
6
Lenvatinib as a therapy for unresectable hepatocellular carcinoma.乐伐替尼作为不可切除肝细胞癌的治疗药物。
Expert Rev Anticancer Ther. 2018 Nov;18(11):1069-1076. doi: 10.1080/14737140.2018.1524297. Epub 2018 Sep 21.
7
Destructive Thyroiditis Induced by Lenvatinib in Three Patients with Hepatocellular Carcinoma.仑伐替尼诱发三例肝细胞癌患者发生破坏性甲状腺炎
Intern Med. 2019 Mar 15;58(6):791-795. doi: 10.2169/internalmedicine.1874-18. Epub 2018 Oct 17.
8
Comparative analysis of liver functional reserve during lenvatinib and sorafenib for advanced hepatocellular carcinoma.乐伐替尼与索拉非尼治疗晚期肝细胞癌期间肝功能储备的比较分析
Hepatol Res. 2020 Jul;50(7):871-884. doi: 10.1111/hepr.13505. Epub 2020 May 15.
9
Optimal management of patients with hepatocellular carcinoma treated with lenvatinib.仑伐替尼治疗肝细胞癌患者的最佳管理。
Expert Opin Drug Saf. 2018 Nov;17(11):1095-1105. doi: 10.1080/14740338.2018.1530212. Epub 2018 Oct 12.
10
[Preclinical study for antitumor mechanism of lenvatinib and clinical studies for hepatocellular carcinoma].[仑伐替尼抗肿瘤机制的临床前研究及肝细胞癌的临床研究]
Nihon Yakurigaku Zasshi. 2019;153(5):242-248. doi: 10.1254/fpj.153.242.
引用本文的文献
1
Targeting STARD4/EGFR axis inhibits growth and overcomes lenvatinib resistance in hepatocellular carcinoma.靶向STARD4/EGFR轴可抑制肝癌生长并克服乐伐替尼耐药性。
Genes Dis. 2025 Feb 15;12(6):101556. doi: 10.1016/j.gendis.2025.101556. eCollection 2025 Nov.
2
Survival Benefit of Adjuvant Treatment with Huaier Granules Plus Lenvatinib in Hepatocellular Carcinoma Patients with Tumors Greater Than 5 cm After Radical Hepatectomy.槐耳颗粒联合乐伐替尼辅助治疗对根治性肝切除术后肿瘤直径大于5cm的肝细胞癌患者的生存获益
J Hepatocell Carcinoma. 2025 Jul 20;12:1495-1507. doi: 10.2147/JHC.S515730. eCollection 2025.
3
Decoding Hepatocellular Carcinoma Metastasis: Molecular Mechanisms, Targeted Therapies, and Potential Biomarkers.解读肝细胞癌转移：分子机制、靶向治疗及潜在生物标志物
Curr Issues Mol Biol. 2025 Apr 8;47(4):263. doi: 10.3390/cimb47040263.
4
The Combined Use of Lenvatinib and Locoregional Therapies for the Management of Hepatocellular Carcinoma.乐伐替尼与局部区域治疗联合用于肝细胞癌的管理
Cancers (Basel). 2025 May 5;17(9):1572. doi: 10.3390/cancers17091572.
5
Systemic Treatment for Unresectable Hepatocellular Carcinoma: A Surgeon's Perspective.不可切除肝细胞癌的全身治疗：外科医生的观点
J Hepatocell Carcinoma. 2025 Feb 26;12:399-413. doi: 10.2147/JHC.S504457. eCollection 2025.
6
Hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitors versus lenvatinib and PD-1 inhibitors for unresectable HCC: a meta-analysis.肝动脉灌注化疗联合乐伐替尼和PD-1抑制剂与乐伐替尼和PD-1抑制剂治疗不可切除肝细胞癌的Meta分析
Front Oncol. 2024 Dec 24;14:1500496. doi: 10.3389/fonc.2024.1500496. eCollection 2024.
7
Efficacy, safety, and biomarker analysis of TACE combined with lenvatinib plus sintilimab in unresectable hepatocellular carcinoma: a real-world study.经导管动脉化疗栓塞术（TACE）联合仑伐替尼和信迪利单抗治疗不可切除肝细胞癌的疗效、安全性和生物标志物分析：一项真实世界研究。
Cancer Immunol Immunother. 2024 Nov 5;74(1):13. doi: 10.1007/s00262-024-03857-5.
8
Effects of three flavonoids on the metabolism of lenvatinib.三种黄酮类化合物对乐伐替尼代谢的影响。
Front Pharmacol. 2024 Aug 20;15:1438259. doi: 10.3389/fphar.2024.1438259. eCollection 2024.
9
Efficiency and Stability of Transarterial Chemoembolization Combined With or Without Lenvatinib for Unresectable Hepatocellular Carcinoma.经导管动脉化疗栓塞联合或不联合仑伐替尼治疗不可切除肝细胞癌的疗效和稳定性。
Turk J Gastroenterol. 2024 Mar;35(3):212-222. doi: 10.5152/tjg.2024.23071.
10
Transarterial Embolization Enhances Programmed Cell Death Ligand 1 Expression and Influences CD8T Lymphocytes Cytotoxicity in an Orthotopic Hepatocellular Carcinoma Rat Model.经导管动脉栓塞增强了原位肝癌大鼠模型中程序性细胞死亡配体 1 的表达并影响 CD8T 淋巴细胞的细胞毒性。
Cardiovasc Intervent Radiol. 2024 Oct;47(10):1372-1381. doi: 10.1007/s00270-024-03813-x. Epub 2024 Aug 5.
本文引用的文献
1
Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial.索拉非尼联合低剂量顺铂和氟尿嘧啶肝动脉灌注化疗与索拉非尼单药治疗晚期肝细胞癌的随机、开放标签、3 期试验（SILIUS）
Lancet Gastroenterol Hepatol. 2018 Jun;3(6):424-432. doi: 10.1016/S2468-1253(18)30078-5. Epub 2018 Apr 7.
2
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.乐伐替尼与索拉非尼用于不可切除肝细胞癌患者一线治疗的比较：一项随机、III 期非劣效性试验。
Lancet. 2018 Mar 24;391(10126):1163-1173. doi: 10.1016/S0140-6736(18)30207-1.
3
Lenvatinib in Advanced Hepatocellular Carcinoma.乐伐替尼用于晚期肝细胞癌
Liver Cancer. 2017 Nov;6(4):253-263. doi: 10.1159/000479573. Epub 2017 Aug 29.
4
Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial.钇[90Y]树脂微球选择性内放射治疗与索拉非尼治疗局部进展期不可切除肝细胞癌的疗效和安全性比较（SARAH）：一项开放标签随机对照 3 期临床试验。
Lancet Oncol. 2017 Dec;18(12):1624-1636. doi: 10.1016/S1470-2045(17)30683-6. Epub 2017 Oct 26.
5
Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial.索拉非尼联合经动脉化疗栓塞治疗不可切除肝细胞癌（TACE 2）：一项随机安慰剂对照、双盲、3 期临床试验。
Lancet Gastroenterol Hepatol. 2017 Aug;2(8):565-575. doi: 10.1016/S2468-1253(17)30156-5. Epub 2017 Jun 23.
6
Dose Finding of Lenvatinib in Subjects With Advanced Hepatocellular Carcinoma Based on Population Pharmacokinetic and Exposure-Response Analyses.基于群体药代动力学和暴露-反应分析的晚期肝细胞癌患者中乐伐替尼的剂量探索
J Clin Pharmacol. 2017 Sep;57(9):1138-1147. doi: 10.1002/jcph.917. Epub 2017 May 31.
7
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.纳武利尤单抗治疗晚期肝细胞癌患者（CheckMate 040）：一项开放标签、非对照、1/2 期剂量递增和扩展试验。
Lancet. 2017 Jun 24;389(10088):2492-2502. doi: 10.1016/S0140-6736(17)31046-2. Epub 2017 Apr 20.
8
Molecular Targeted Agents for Hepatocellular Carcinoma: Current Status and Future Perspectives.肝细胞癌的分子靶向药物：现状与未来展望
Liver Cancer. 2017 Feb;6(2):101-112. doi: 10.1159/000452138. Epub 2016 Dec 15.
9
Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC.mRECIST 作为晚期 HCC 总生存期的预测指标和潜在替代终点的客观反应。
J Hepatol. 2017 Jun;66(6):1166-1172. doi: 10.1016/j.jhep.2017.01.012. Epub 2017 Jan 26.
10
FGF19/FGFR4 signaling contributes to the resistance of hepatocellular carcinoma to sorafenib.成纤维细胞生长因子19/成纤维细胞生长因子受体4信号通路导致肝细胞癌对索拉非尼产生耐药性。
J Exp Clin Cancer Res. 2017 Jan 9;36(1):8. doi: 10.1186/s13046-016-0478-9.
Zotero 插件